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Introduction 
Off-label (unlabelled or unapproved) use of approved product refers to the use of 
an approved product in a scenario that is not included or is disclaimed in the 
product information. Examples include use for a different indication, in a 
different patient age range-group, different dose or different route of 
administration to that which is approved by regulatory authorities.    
Genetech (San Francisco, CA) developed a monoclonal antibody against vascular 
endothelial growth factor (VEGF) that was as a cancer therapy with the idea that 
reducing the vascular supply to a tumor may inhibit growth of the cancer. 
 VEGF is a protein and is the most important growth factor for neovascularization in a variety of tissues 
including the eye.  
VEGF plays a pivotal role in the development of pathologic angiogenesis in ischemic and inflammatory 
diseases such as proliferative diabetic retinopathy, central retinal vein occlusion and retinopathy of 
prematurity.  Bevacizumab (avastin Genetech Inc, San Francisco, CA) is a full-length, humanized 
monoclonal antibody against VEGF. It is currently approved as an intravenous treatment for metastatic 
colorectal cancer.  
There is anecdotal evidence that off-label use intravitreal bevacizumab improves short-term visual outcomes 
in patient with neovascular age-related macular degeneration age-related macular degeneration AMD3. 
Intravitreal administration of bevacizumab has recently been reported to be of benefit in choroidal 
neovascular membrane1-2, retinal neovascularization in proliferative diabetic retinopathy and iris 
neovascularization 4-5. 
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Case Report – 1 
 
 35- year- old woman presented with 
deterioration of vision in her left eye. 
Visual acuity in the left eye was    
6/60 and 6/6 in the right eye. The right eye 
was normal (Figure 1)  
 
 
 Figure 1: normal fundus of the right eye 
 





 The left eye examination revealed peri- 
papillary choroidal neovascular membrane 
involving the papillo-macular region with 
sub-retinal hemorrhage and retinal edema 
(Figure 2).due to  unseen pathology, 
possiblely para-macular telangectasia or 
choroidal tear.  
 
 
Figure 2: Patient with per papillary choroidal 
neovascular membrane involving the papillo-macular 
region in the left eye. 
 
The patient was treated with an off-label   
intravitreal bevacizumab injection of 2.5 mg     
A 
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(0.1 ml of avastin Genetech Inc, San 
Francisco, CA at concentration of 25 mg /ml)  
The consent of the patient was obtained   after 
explaining the risks and benefits of the 
treatment. 
 Three months following the intravitreal 
injection the visual acuity of the left eye 




Figure 3: Patient left eye after treatment 
 
We observed rapid resolution of the choroidal 
neovascular membrane and sub-retinal 
hemorrhage and retinal edema with an 
excellent improvement in visual acuity.  
 
Case Report -2  
 
A 30- year-old man presented with 
Metamorphopsia of the right eye. He was 
systemically healthy Visual acuity was 1/60 
in the right eye and 6/5 left eye respectively. 
Examination of the right eye revealed 
multifocal choriditis with choroidal 
neovascular membrane. A fluoresceine 
Angiogram was performed (Figure 4) 
The left eye was within normal limits. The 
patient was treated with an off-label   
intravitreal bevacizumab injection of 2.5 mg 
of   (0.1 ml of avastin Genetech Inc, San 
Francisco, CA at a concentration of 25 mg 
/ml) 
The consent of the patient was obtained   after 








Figure 4: patient with multi-focal choriditis of the right 
eye and fluoresceine angiography demonstrated 
multifocal lesions affecting retinal pigment epithelium 
and choroid. 
 
The condition improved on follow up and 
after 3 months the best vision of the right eye 
was 6/6 and the lesion resolved with only 
persistence extra foveal scar (Figure 5).  
 
 
Figure 5: patient right eye after treatment 
 
Discussion 
Bevacizumab was primarily developed for the 
treatment of a variety of solid tumors 3-5 .In 
2004, the FDA approved bevacizumab for 
treatment of metastatic colorectal cancer in 
combination with standard chemotherapy 4 
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It also showed benefit of improved vision in 
neovascular AMD and reduction of macular 
edema in diabetic retinopathy.  
Most of the published reports are either small 
case series or anecdotal reports. However, 
extensive publications on intravitreal 
bevacizumab suggest that the drug has shown 
its beneficial effect at least in short-term 
follow-up and appears to be a part of 
preferred practice in the treatment of the CNV 
or retinal vascular disease.  
 No systemic or serious drug-related adverse 
events were observed. Subconjuctival 
hemorrhage and conjunctival hyperemia were 
observed frequently at the injection site.  
Ocular complications due to injection 
procedure like both infectious and sterile 
endophthalmitis were reported in one study 7 
the incidence of culture-positive 
endophthalmitis was 0.87%, while in other 
reports no case was observed; this difference 
could be due to following strict asepsis during 
the drug administration. Sterile 
endophthalmitis could occur due to solvent 
agent.   
Intravitreal Bevacizumab has also been used 
in the treatment of aggressive posterior 
retinopathy of prematurity 6. Anecdotal 
reports also show the effect of intravitreal 
bevacizumab in the treatment of central 
retinal vein occlusion, branch retinal vein 
occlusion, and neovascular glaucoma. 
The cases we report here were pooled from 
different patients who received bevacizumab 
for treatment of neovascular membrane due to 
different causes as age-related macular 
degeneration, central retinal vein occlusion, 
post traumatic choroidal tears, or due angioid 
streaks. 
All patients received intravitreal bevacizumab 
2.5mg/0.1ml under good aseptic conditions . 
No case had ocular or systematic 
complications. 
All   cases gained best vision and resolution 
of the fundus lesions with in 3 months of 
follow- up.    
   
These cases illustrates that intravitreal 
bevacizumab has possible role in the 
treatment of the above  conditions with 
regression of neovascular membrane and 
subsequent visual improvement ,although a 
much longer follow up and a larger 
prospective study is required to reach a 
conclusive result.   
 
References  
1. Rosenfeld PJ, Moshfegh AA, Puliafito CA.  Optical 
coherence tomography findings after intravitreal 
injection of bevacizumab (Avastin) for neovascular age 
related macular degeneration. Ophthalmic surgery 
lasers imaging 2005; 36:331-5.  
2. Avery RL, pieramjci DJ, Rabena MD et al. 
Intravitreal injection of bevacizumab (Avastin) for 
neovascular age related macular degeneration. 
Ophthalmology 2205; 113:363-72. 
3. Shams N, Lanchulev T. Role of vascular endothelial 
growth factor in ocular angiogenesis. Ophthalmol Clin 
North Am 2006; 19:335-44. 
4. Avery RL. regression of retinal and iris 
neovascularization after  intravitreal bevacizumab ( 
Avastin ) treatment retina 2006 ; 26:352-4 
5. Davidorf FH, Mouser JG, Derick RJ. Rapid 
improvement of rubeosis iridis from a single 
bevacizumab (Avastin) injection. Retina 2006; 26:354-
6. 
6. Shah PK, Narendran V, Tawansy KA et al. 
Intravitreal bevacizumab (avastin)for post laser anterior  
ischemia in aggressive retinopathy of prematurity 
.Indian  J Opthalmology 2007;55:75-6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
